| Identification | Back Directory | [Name]
Cediranib | [CAS]
288383-20-0 | [Synonyms]
AZD2171
Recentin
Cadiranib
Cediranib
NSC-732208
Cediranib R
Cediranib, >=99%
Cediranib (AZD217)
Cediranib(AZD2171)
Cadiranib (AZD2171)
Cediranib dihydrochloride
4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
4-((4-fluoro-2-Methyl-1H-indol-5-yl)oxy)-6-Methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
Cediranib
4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline Cediranib (AZD2171) | [EINECS(EC#)]
670-946-2 | [Molecular Formula]
C25H27FN4O3 | [MDL Number]
MFCD09954115 | [MOL File]
288383-20-0.mol | [Molecular Weight]
450.51 |
| Chemical Properties | Back Directory | [Melting point ]
135-138°C | [Boiling point ]
626.6±55.0 °C(Predicted) | [density ]
1.285 | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
Acetone (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
16.14±0.30(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Uses]
Cediranib (AZD2171) inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively. | [Description]
Receptors for VEGF have central roles in vasculogenesis and angiogenesis and thus serve as targets for cancer therapy.1,2 Cediranib is a potent inhibitor of VEGF receptor tyrosine kinases, including VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively).3 It also potently inhibits a variety of other receptor and non-receptor tyrosine kinases, including several in the platelet-derived growth factor, fibroblast growth factor, and endothelial growth factor receptor families.3,4 Cediranib blocks tubule formation by human umbilical vein endothelial cells in vitro and prevents angiogenesis as well as xenograft tumor growth in vivo.3 Because of these effects, cediranib has potential use in a range of cancers.5,6,7 | [Definition]
ChEBI: 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline is an aromatic ether. | [storage]
Store at -20°C | [References]
[1] wedge sr, kendrew j, hennequin lf, valentine pj, barry st, brave sr, smith nr, james nh, dukes m, curwen jo, chester r, jackson ja, boffey sj, kilburn ll, barnett s, richmond gh, wadsworth pf, walker m, bigley al, taylor st, cooper l, beck s, jürgensmeier jm, ogilvie dj. azd2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. cancer res. 2005 may 15;65(10):4389-400. |
| Questions And Answer | Back Directory | [Anticancer drugs]
Cediranib is an oral anticancer drug , it is successfully developed by the US AstraZeneca company , its trade name is recentin, this product is an efficient VEGFR tyrosine kinase inhibitor, it is capable of inhibiting all known VEGFR tyrosine kinases ( including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR). Cediranib can inhibit VEGF-induced angiogenesis, neovascularization survival and human tumor xenograft cell growth.Clinical trail phase I for non-small cell lung cancer (abbreviated NSCLC) patients shows that cediranib in combination with PC programs has a significant antitumor effect . Clinical trail phaseⅡ/Ⅲ BR24 focuses on using cediranib 30mg as a first-line treatment of NSCLC ,which demonstrates that it has anti-tumor effect, but it has a higher incidence of adverse events, including diarrhea, dehydration, hand-foot syndrome, hypertension and neutropenia disease. Therefore, there is the decision to stop clinical trials. Repeated assessments about toxicity and dose of the combination of drugs suggest that part of the adverse effects are dose-related , dose reduction may be tried to improve drug tolerance. In view of this conclusion, in 2009, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) launched a cediranib clinical trail phase Ⅲ (BR29) for progressive NSCLC patients , the dose was adjusted to 20mg. The results have not been reported.
In 2009 ,European Society for Medical Oncology (ESMO) Annual report which is about cediranib treatment of metastatic renal cell carcinoma (referred mRCC) clinical trail phase II shows that cediranib treatment group tumor volume reducing rate is higher than the placebo group. Zurita tested Cediranib pretreatment serum cytokines and angiogenic factors ,and found that patients having low IL-10, VEGF, PIGF, SCF and MIG concentration during baseline time , have the more obvious tumor volume reduction after treatment.
The above information is edited by the chemicalbook of Tian Ye.
|
|
|